methyl 4-(2-nitrostyryl)benzoate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: methyl 4-(2-nitrostyryl)benzoate
• 英文别名: methyl (E)-4-(2-nitrostyryl)benzoate；methyl 4-[(E)-2-(2-nitrophenyl)ethenyl]benzoate
• 化学式: C₁₆H₁₃NO₄
• 分子量: 283.284
• InChiKey: DBSKGVBFJHKARW-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 4-(2-nitrostyryl)benzoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 以77%的产率得到methyl 4-(2-aminophenethyl)benzoate
  参考文献：
  名称：

  Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response

  摘要：

  Microtubule-targeting agents (MTA) have enjoyed significant clinical success for decades. However, several mechanisms may cause inactivation of such drugs, leading to acquired resistance in patients treated with them. Therefore, drugs containing a stilbene-like skeleton and possessing dual inhibitory activity may provide a new and differentiated treatment for patients to overcome challenging acquired resistance. A new compound (16c) displays promising anticancer activity with GI(50) of 22 +/- 2 and 12 +/- 0.1 nM in vincristine-resistant nasopharyngeal (KB-Vin) cancer cells and etoposide-resistant nasopharyngeal (KB-7D) cancer cells and is better than vincristine, etoposide, ABT-751, and MS-275. A mechanistic study revealed that 16c interferes with the cell cycle distribution and induces cell cycle arrest at the G2/M phase and severe mitotic spindle defects followed by apoptosis. In addition, it produces much more significant cytotoxicity than vincristine and etoposide in the corresponding resistant cells, indicating that it may be a promising candidate to overcome drug resistance in cancer cells. Compound 16c also displays inhibitory activity against HDAC 1 and HDAC 2 with IC50 values of 1.07 mu M, and 1.47 mu M, respectively. These findings may lead to a new type of structural motif for future development of drugs that could overcome acquired resistance to MTAs. (c) 2020 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112158
• 作为产物：
  描述：

  (4-甲氧羰基苄基)三苯基溴化膦 、 邻硝基苯甲醛 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以56%的产率得到methyl 4-(2-nitrostyryl)benzoate
  参考文献：
  名称：

  Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response

  摘要：

  Microtubule-targeting agents (MTA) have enjoyed significant clinical success for decades. However, several mechanisms may cause inactivation of such drugs, leading to acquired resistance in patients treated with them. Therefore, drugs containing a stilbene-like skeleton and possessing dual inhibitory activity may provide a new and differentiated treatment for patients to overcome challenging acquired resistance. A new compound (16c) displays promising anticancer activity with GI(50) of 22 +/- 2 and 12 +/- 0.1 nM in vincristine-resistant nasopharyngeal (KB-Vin) cancer cells and etoposide-resistant nasopharyngeal (KB-7D) cancer cells and is better than vincristine, etoposide, ABT-751, and MS-275. A mechanistic study revealed that 16c interferes with the cell cycle distribution and induces cell cycle arrest at the G2/M phase and severe mitotic spindle defects followed by apoptosis. In addition, it produces much more significant cytotoxicity than vincristine and etoposide in the corresponding resistant cells, indicating that it may be a promising candidate to overcome drug resistance in cancer cells. Compound 16c also displays inhibitory activity against HDAC 1 and HDAC 2 with IC50 values of 1.07 mu M, and 1.47 mu M, respectively. These findings may lead to a new type of structural motif for future development of drugs that could overcome acquired resistance to MTAs. (c) 2020 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112158

文献信息

• Direct Synthesis of Unprotected Indolines Through Intramolecular sp³ C−H Amination Using Nitroarenes as Aryl Nitrene Precursors
  作者：Giedre Sirvinskaite、Celine S. Nardo、Patrick Müller、Aurelio C. Gasser、Bill Morandi

  DOI：10.1002/chem.202301978

  日期：2023.9.26

  benzylic sp3 C−H amination is disclosed using aryl nitro compounds as aryl nitrene precursors. Organosilicon reagent N,N’-bis(trimethylsilyl)-4,4’-bipyridinylidene (Si-DHBP) served as an efficient reductant in the transformation, enabling the in situ generation of aryl nitrene species for the synthesis of 2-arylindolines from the corresponding nitroarene compounds.

  公开了使用芳基硝基化合物作为芳基氮烯前体的无金属分子内苄基 sp 3 CH 胺化。有机硅试剂N , N'-双(三甲基甲硅烷基)-4,4'-联吡啶亚基 (Si-DHBP) 在转化中作为有效的还原剂，能够原位生成芳基氮烯，用于从 2-芳基二氢吲哚合成相应的硝基芳烃化合物。
• BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0832061A1

  公开（公告）日：1998-04-01
• US6054457A
  申请人：——

  公开号：US6054457A

  公开（公告）日：2000-04-25
• [EN] BENZAMIDE DERIVATIVES AND THEIR USE AS VASOPRESSIN ANTAGONISTS<br/>[FR] DERIVES DE TYPE BENZAMIDE ET LEUR UTILISATION COMME ANTAGONISTES DE LA VASOPRESSINE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1996041795A1

  公开（公告）日：1996-12-27

  (EN) This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc., and represented by general formula (I), wherein R1 is aryl optionally substituted with lower alkoxy, etc., R2 is lower alkyl, etc., R3 is hydrogen, etc., R4 is lower alkoxy, etc., R5 is hydrogen, etc., A is NH, etc., E is (a), etc., X is -CH=CH-, -CH=N-, or S, and Y is CH or N, and pharmaceutically acceptable salts thereof, to processes for preparation thereof and to a pharmaceutical composition comprising the same.(FR) La présente invention concerne d'une part des dérivés de type benzamide présentant notamment une activité antagoniste de la vasopressine et d'autre part des sels de ces dérivés admis en pharmacologie. L'invention concerne également des procédés de préparation de ces dérivés ou sels ainsi que des compositions à base de ces dérivés ou sels. Ces dérivés sont représentés par la formule générale (I) dans laquelle R1 est aryle à substitution alcoxy inférieur éventuelle, R2 est alkyle inférieur, R3 est alcoxy inférieur, R5 est hydrogène, A est NH, E est (a), X est -CH=CH-, -CH=N- ou S, et Y est CH ou N.
• Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response
  作者：Wei-Cheng Wu、Yi-Min Liu、Mei-Hsiang Lin、Yu-Hsuan Liao、Mei-Jung Lai、Hsun-Yueh Chuang、To-Yu Hung、Chun-Han Chen、Jing-Ping Liou

  DOI：10.1016/j.ejmech.2020.112158

  日期：2020.4

  Microtubule-targeting agents (MTA) have enjoyed significant clinical success for decades. However, several mechanisms may cause inactivation of such drugs, leading to acquired resistance in patients treated with them. Therefore, drugs containing a stilbene-like skeleton and possessing dual inhibitory activity may provide a new and differentiated treatment for patients to overcome challenging acquired resistance. A new compound (16c) displays promising anticancer activity with GI(50) of 22 +/- 2 and 12 +/- 0.1 nM in vincristine-resistant nasopharyngeal (KB-Vin) cancer cells and etoposide-resistant nasopharyngeal (KB-7D) cancer cells and is better than vincristine, etoposide, ABT-751, and MS-275. A mechanistic study revealed that 16c interferes with the cell cycle distribution and induces cell cycle arrest at the G2/M phase and severe mitotic spindle defects followed by apoptosis. In addition, it produces much more significant cytotoxicity than vincristine and etoposide in the corresponding resistant cells, indicating that it may be a promising candidate to overcome drug resistance in cancer cells. Compound 16c also displays inhibitory activity against HDAC 1 and HDAC 2 with IC50 values of 1.07 mu M, and 1.47 mu M, respectively. These findings may lead to a new type of structural motif for future development of drugs that could overcome acquired resistance to MTAs. (c) 2020 Published by Elsevier Masson SAS.